OREANDA-NEWS. Veropharm [RTS: VRPH, MICEX: VFRM] announced its preliminary sales and operational results for the first nine months of 2007, according to the management’s accounting report.

According to Veropharm management’s estimates, Veropharm’s net sales totaled $92.9 mln in the first nine months of 2007. Sales of Veropharm’s finished goods increased 32% y-o-y, totaling $90.2 mln in the first nine months of 2007. Sales of prescription drugs in this period totaled $49.9 mln, demonstrating a 39% y-o-y growth. The percentage of prescription drugs in the total sales volume was 55.3%(of finished product sales).Sales of traditional drugs totaled $15.1 mln, demonstrating a 33% y-o-y growth. The percentage of traditional drugs in the total sales volume was 16.7%. Sales of adhesive bandages totaled $17.5 mln, demonstrating a 15% y-o-y growth. The percentage of adhesive bandages in the total sales volume was 19.4%. Sales of non-prescription drugs totaled $7.7 mln, demonstrating a 31% y-o-y growth. The percentage of non-prescription drugs in the total sales volume was 8.6%.

Veropharm’s sales within the Federal Reimbursement Program (FRP) totaled $4.3 mln, or 5% of the company’s sales. In the same period in 2006, Veropharm’s sales within the program totaled $5.2 mln, or 8% of the company’s sales. Veropharm’s sales in Russia accounted for 95.8% of the company’s sales in the first nine months of 2007.

Prescription Drugs Segment
Sales of Veropharm’s five best-selling prescription drugs in the first nine months of 2007 totaled $21.3 mln, or 43% of all prescription drugs sales and 24% of the company’s overall sales.

Traditional Drugs Segment
Sales in the traditional drugs segment continue to grow due to reduced production volume by other Russian pharmaceutical enterprises and to stable demand for these medicines. Sales of Veropharm’s five best-selling traditional drugs in the first nine months of 2007 totaled $8.1 mln, or 54% of all traditional drugs sales and 9% of the company’s overall sales.

During the first nine months of 2007, Veropharm successfully registered five new drugs.

Debt
At the end of the first nine months of 2007, Veropharm debt was $23.9 mln.